A scientist in AIRNA's research labs in Tübingen, Germany (Credit: AIRNA)

RNA edit­ing start­up launch­es with $30M based on Stan­ford and Uni­ver­si­ty of Tübin­gen re­search

The race to de­vel­op new ther­a­pies that pre­cise­ly ed­it short-lived RNA mol­e­cules in­stead of mak­ing ir­re­versible changes to DNA is heat­ing up. A new en­trant to the grow­ing field emerged from stealth Tues­day morn­ing with a $30 mil­lion ini­tial fi­nanc­ing round led by ARCH Ven­ture Part­ners to make RNA edit­ing ther­a­pies for both rare and com­mon dis­eases.

The start­up, called AIR­NA, was co-found­ed in 2021 by Thorsten Stafforst — a Uni­ver­si­ty of Tübin­gen bio­chemist whose work over the past decade helped spark in­ter­est in RNA edit­ing ther­a­pies — and Jin Bil­ly Li, a Stan­ford Uni­ver­si­ty bi­ol­o­gist who has stud­ied the en­zymes that pow­er RNA edit­ing in na­ture since 2006.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.